Skip to content

NMIN releases first round of Research Investment

On August 21, 2019, the Board of Directors approved NMIN’s initial investments of $4.3M in nanomedicines research. Over a two-year period, NMIN will support 20 innovative projects led by Canadian leaders in nanomedicine drug delivery, gene therapy and diagnostics.

These projects, hosted at six research centres across Canada, span a range of technologies (from neutrophil encapsulation to LNP systems) applied to a range of illnesses (from cancer to diabetes and eye disease).

Read about NMIN’s first round of research investment in NMIN’s November 2019 Newsletter

Details regarding each project are available through NMIN’s Project Database

Information about the lead investigators for NMIN’s projects can be found in NMIN’s Researcher Database.